ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1409

The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)

Conall Mac Gearailt1, Rebecca O'Farrell2, Mohamed Eltahir3, Brian Hallahan3, Andrew Smyth4, Finbar O'Shea5 and Gillian Fitzgerald3, 1Galway University Hospital, Galway, Galway, Ireland, 2Sligo University Hospital, Sligo, Ireland, 3Galway University Hospital, Galway, Ireland, 4University of Galway, Galway, Ireland, 5St James's Hospital and Trinity College Dublin, Dublin, Dublin, Ireland

Meeting: ACR Convergence 2025

Keywords: depression, Disease Activity, Epidemiology, registry, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The burden of comorbidities in Axial Spondyloarthritis (axSpA) is increasingly recognised and contributes to the concept of difficult-to-treat axSpA (D2T-axSpA). The need to assess for non-inflammatory causes of uncontrolled disease is vital. We aim to characterise the prevalence and impact of depression in an Irish axSpA cohort.

Methods: The Ankylosing Spondylitis Registry of Ireland is a well-established observational multi-centre study of clinically diagnosed axSpA patients in Ireland. This study was conducted within the framework of ASRI. Depression was identified using a participant-reported physician-confirmed diagnosis.Comorbidities and medication history were compiled using structured interviews. Validated outcome measures including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Health Assessment Questionnaire (HAQ), Bath Ankylosing Spondylitis Functional Index (BASFI) and Ankylosing Spondylitis Quality of Life (ASQoL) scale were recorded.

Results: At analysis, 914 participants were enrolled in the registry (75.3% male, mean age 45.85). Basic demographics are available at Table 1. In total, depression was reported in 94 (10.3%) participants. A significant association between age group and depression (p=0.049) was observed, with higher prevalence in older cohorts.Participants with comorbid depression had a higher prevalence of peripheral manifestations of axSpA compared to their peers without depression: peripheral arthritis was more common in those with depression (42.9% vs 29.6% without depression; p< 0.01); 27.5% of patients with depression had enthesitis vs 16.8% of those without depression (p< 0.01); psoriasis was present in 25.3% of cases with depression vs 15.7% of those without depression (p=0.02). No differences were found in dactylitis (6.6% in both groups; p=0.60) or inflammatory bowel disease (13.3% vs 10.4%; p=0.24). No statistical difference between genders was seen when assessing depression in this cohort (11.1% male vs 13% female, p=0.59).Participants with depression had significantly (p< 0.001) higher disease activity scores compared to those without, including BASDAI (5.04 vs 3.81), HAQ (0.76 vs 0.49), BASFI (4.56 vs 3.46) and ASQoL (9.93 vs 6.07) (Figure 1). Unemployment status also differed significantly (p< 0.01) between those with (28.7%) and without depression (16.6%). Depression was also more prevalent in homemakers (13.8% vs 4.9%; p< 0.01).

Conclusion: In an Irish axSpA cohort, depression is a prominent factor affecting approximately 1 in 10 participants. Depression is significantly associated with higher disease activity, poorer functional status, and increased peripheral manifestations indicating a greater burden of disease in these patients.

Supporting image 1

Supporting image 2


Disclosures: C. Mac Gearailt: AbbVie/Abbott, 12, Support to attend conference, Celltrion, 12, Support to attend conference, Pfizer, 12, Support to attend conference; R. O'Farrell: None; M. Eltahir: Novartis, 12, Support to attend conference; B. Hallahan: None; A. Smyth: None; F. O'Shea: None; G. Fitzgerald: None.

To cite this abstract in AMA style:

Mac Gearailt C, O'Farrell R, Eltahir M, Hallahan B, Smyth A, O'Shea F, Fitzgerald G. The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI) [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-depression-in-axial-spondyloarthritis-epidemiological-insights-from-the-ankylosing-spondylitis-registry-of-ireland-asri/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-depression-in-axial-spondyloarthritis-epidemiological-insights-from-the-ankylosing-spondylitis-registry-of-ireland-asri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology